Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

Peter A. Cassileth, David P. Harrington, Frederick R. Appelbaum, Hillard M. Lazarus, Jacob M. Rowe, Elisabeth M. Paietta, Cheryl Willman, David D. Hurd, John M. Bennett, Karl G. Blume, David R. Head, Peter H. Wiernik

Research output: Contribution to journalArticle

518 Citations (Scopus)

Abstract

Background: In young adults with acute myeloid leukemia, intensive chemotherapy during the initial remission improves the long-term outcome, but the role of bone marrow transplantation is uncertain. We compared high-dose cytarabine with autologous or allogeneic marrow transplantation during the first remission of acute myeloid leukemia. Methods: Previously untreated adolescents and adults 16 to 55 years of age who had acute myeloid leukemia received standard induction chemotherapy. After complete remission had been achieved, idarubicin (two days) and cytarabine (five days) were administered. Patients with histocompatible siblings were offered allogeneic marrow transplantation, whereas the remaining patients were randomly assigned to receive a single course of high-dose cytarabine or transplantation of autologous marrow treated with perfosfamide (4-hydroperoxycyclophosphamide). Oral busulfan and intravenous cyclophosphamide were used as preparative regimens for both allogeneic and autologous marrow transplantation. The end points were survival from the time of complete remission and disease-free survival. Results: In an intention-to-treat analysis, we found no significant differences in disease-free survival among patients receiving high-dose chemotherapy, those undergoing autologous bone marrow transplantation, and those undergoing allogeneic marrow transplantation. The median follow-up was four years. Survival after complete remission was somewhat better after chemotherapy than after autologous marrow transplantation (P=0.05). There was a marginal advantage in terms of overall survival with chemotherapy as compared with allogeneic marrow transplantation (P=0.04). Conclusions: A postinduction course of high-dose cytarabine can provide equivalent disease- free survival and somewhat better overall survival than autologous marrow transplantation in adults with acute myeloid leukemia.

Original languageEnglish (US)
Pages (from-to)1649-1656
Number of pages8
JournalNew England Journal of Medicine
Volume339
Issue number23
DOIs
StatePublished - Dec 3 1998

Fingerprint

Homologous Transplantation
Bone Marrow Transplantation
Acute Myeloid Leukemia
Bone Marrow
Autologous Transplantation
Drug Therapy
perfosfamide
Cytarabine
Disease-Free Survival
Survival
Idarubicin
Busulfan
Induction Chemotherapy
Intention to Treat Analysis
Cyclophosphamide
Siblings
Young Adult

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. / Cassileth, Peter A.; Harrington, David P.; Appelbaum, Frederick R.; Lazarus, Hillard M.; Rowe, Jacob M.; Paietta, Elisabeth M.; Willman, Cheryl; Hurd, David D.; Bennett, John M.; Blume, Karl G.; Head, David R.; Wiernik, Peter H.

In: New England Journal of Medicine, Vol. 339, No. 23, 03.12.1998, p. 1649-1656.

Research output: Contribution to journalArticle

Cassileth, PA, Harrington, DP, Appelbaum, FR, Lazarus, HM, Rowe, JM, Paietta, EM, Willman, C, Hurd, DD, Bennett, JM, Blume, KG, Head, DR & Wiernik, PH 1998, 'Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission', New England Journal of Medicine, vol. 339, no. 23, pp. 1649-1656. https://doi.org/10.1056/NEJM199812033392301
Cassileth, Peter A. ; Harrington, David P. ; Appelbaum, Frederick R. ; Lazarus, Hillard M. ; Rowe, Jacob M. ; Paietta, Elisabeth M. ; Willman, Cheryl ; Hurd, David D. ; Bennett, John M. ; Blume, Karl G. ; Head, David R. ; Wiernik, Peter H. / Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. In: New England Journal of Medicine. 1998 ; Vol. 339, No. 23. pp. 1649-1656.
@article{707f03724b16433c922b92cc1a3d1a26,
title = "Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission",
abstract = "Background: In young adults with acute myeloid leukemia, intensive chemotherapy during the initial remission improves the long-term outcome, but the role of bone marrow transplantation is uncertain. We compared high-dose cytarabine with autologous or allogeneic marrow transplantation during the first remission of acute myeloid leukemia. Methods: Previously untreated adolescents and adults 16 to 55 years of age who had acute myeloid leukemia received standard induction chemotherapy. After complete remission had been achieved, idarubicin (two days) and cytarabine (five days) were administered. Patients with histocompatible siblings were offered allogeneic marrow transplantation, whereas the remaining patients were randomly assigned to receive a single course of high-dose cytarabine or transplantation of autologous marrow treated with perfosfamide (4-hydroperoxycyclophosphamide). Oral busulfan and intravenous cyclophosphamide were used as preparative regimens for both allogeneic and autologous marrow transplantation. The end points were survival from the time of complete remission and disease-free survival. Results: In an intention-to-treat analysis, we found no significant differences in disease-free survival among patients receiving high-dose chemotherapy, those undergoing autologous bone marrow transplantation, and those undergoing allogeneic marrow transplantation. The median follow-up was four years. Survival after complete remission was somewhat better after chemotherapy than after autologous marrow transplantation (P=0.05). There was a marginal advantage in terms of overall survival with chemotherapy as compared with allogeneic marrow transplantation (P=0.04). Conclusions: A postinduction course of high-dose cytarabine can provide equivalent disease- free survival and somewhat better overall survival than autologous marrow transplantation in adults with acute myeloid leukemia.",
author = "Cassileth, {Peter A.} and Harrington, {David P.} and Appelbaum, {Frederick R.} and Lazarus, {Hillard M.} and Rowe, {Jacob M.} and Paietta, {Elisabeth M.} and Cheryl Willman and Hurd, {David D.} and Bennett, {John M.} and Blume, {Karl G.} and Head, {David R.} and Wiernik, {Peter H.}",
year = "1998",
month = "12",
day = "3",
doi = "10.1056/NEJM199812033392301",
language = "English (US)",
volume = "339",
pages = "1649--1656",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "23",

}

TY - JOUR

T1 - Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

AU - Cassileth, Peter A.

AU - Harrington, David P.

AU - Appelbaum, Frederick R.

AU - Lazarus, Hillard M.

AU - Rowe, Jacob M.

AU - Paietta, Elisabeth M.

AU - Willman, Cheryl

AU - Hurd, David D.

AU - Bennett, John M.

AU - Blume, Karl G.

AU - Head, David R.

AU - Wiernik, Peter H.

PY - 1998/12/3

Y1 - 1998/12/3

N2 - Background: In young adults with acute myeloid leukemia, intensive chemotherapy during the initial remission improves the long-term outcome, but the role of bone marrow transplantation is uncertain. We compared high-dose cytarabine with autologous or allogeneic marrow transplantation during the first remission of acute myeloid leukemia. Methods: Previously untreated adolescents and adults 16 to 55 years of age who had acute myeloid leukemia received standard induction chemotherapy. After complete remission had been achieved, idarubicin (two days) and cytarabine (five days) were administered. Patients with histocompatible siblings were offered allogeneic marrow transplantation, whereas the remaining patients were randomly assigned to receive a single course of high-dose cytarabine or transplantation of autologous marrow treated with perfosfamide (4-hydroperoxycyclophosphamide). Oral busulfan and intravenous cyclophosphamide were used as preparative regimens for both allogeneic and autologous marrow transplantation. The end points were survival from the time of complete remission and disease-free survival. Results: In an intention-to-treat analysis, we found no significant differences in disease-free survival among patients receiving high-dose chemotherapy, those undergoing autologous bone marrow transplantation, and those undergoing allogeneic marrow transplantation. The median follow-up was four years. Survival after complete remission was somewhat better after chemotherapy than after autologous marrow transplantation (P=0.05). There was a marginal advantage in terms of overall survival with chemotherapy as compared with allogeneic marrow transplantation (P=0.04). Conclusions: A postinduction course of high-dose cytarabine can provide equivalent disease- free survival and somewhat better overall survival than autologous marrow transplantation in adults with acute myeloid leukemia.

AB - Background: In young adults with acute myeloid leukemia, intensive chemotherapy during the initial remission improves the long-term outcome, but the role of bone marrow transplantation is uncertain. We compared high-dose cytarabine with autologous or allogeneic marrow transplantation during the first remission of acute myeloid leukemia. Methods: Previously untreated adolescents and adults 16 to 55 years of age who had acute myeloid leukemia received standard induction chemotherapy. After complete remission had been achieved, idarubicin (two days) and cytarabine (five days) were administered. Patients with histocompatible siblings were offered allogeneic marrow transplantation, whereas the remaining patients were randomly assigned to receive a single course of high-dose cytarabine or transplantation of autologous marrow treated with perfosfamide (4-hydroperoxycyclophosphamide). Oral busulfan and intravenous cyclophosphamide were used as preparative regimens for both allogeneic and autologous marrow transplantation. The end points were survival from the time of complete remission and disease-free survival. Results: In an intention-to-treat analysis, we found no significant differences in disease-free survival among patients receiving high-dose chemotherapy, those undergoing autologous bone marrow transplantation, and those undergoing allogeneic marrow transplantation. The median follow-up was four years. Survival after complete remission was somewhat better after chemotherapy than after autologous marrow transplantation (P=0.05). There was a marginal advantage in terms of overall survival with chemotherapy as compared with allogeneic marrow transplantation (P=0.04). Conclusions: A postinduction course of high-dose cytarabine can provide equivalent disease- free survival and somewhat better overall survival than autologous marrow transplantation in adults with acute myeloid leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0032480930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032480930&partnerID=8YFLogxK

U2 - 10.1056/NEJM199812033392301

DO - 10.1056/NEJM199812033392301

M3 - Article

C2 - 9834301

AN - SCOPUS:0032480930

VL - 339

SP - 1649

EP - 1656

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 23

ER -